
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is positioned for substantial growth in the respiratory care market, supported by a projected revenue increase of over high single digits (HSD%) in FY26, driven by rising sleep apnea diagnoses and an ageing population. The company has also demonstrated its commitment to returning value to shareholders through consistent dividend increases and an aggressive share repurchase strategy, while simultaneously investing in digital health initiatives. Furthermore, ResMed achieved a notable 12% year-over-year revenue increase in masks and other products across the U.S., Canada, and LATAM, highlighting its robust performance in key markets.
Bears say
The analysis indicates that ResMed may face medium-term challenges due to the increasing adoption of GLP-1 drugs, which are anticipated to disrupt volumes of Positive Airway Pressure (PAP) devices. Despite the company outpacing market growth, there is concern that the uptake of GLP-1 therapies could negatively impact future sales of its masks and devices. This creates a cautious outlook for ResMed given the potential for slowed revenue growth driven by changing treatment paradigms in sleep apnea management.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares